Alpine Global Management’s Arbutus Biopharma ABUS Stock Holding History

Alpine Global Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,198	Closed	-$24K	–	136
2022 Q4	$24K	Buy	+10,198	New	+$24.4K	0.01%	419
2021 Q1	–	Sell	-35,825	Closed	-$127K	–	306
2020 Q4	$127K	Buy	+35,825	New	+$125K	0.03%	145
2016 Q2	–	Sell	-10,434	Closed	-$43K	–	186
2016 Q1	$43K	Buy	+10,434	New	+$37.3K	0.01%	145

Other funds holding ABUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alpine Global Management's ABUS Position: Q1 2023 in Review

Alpine Global Management sold out of Arbutus Biopharma (ABUS) in Q1 2023, closing a stake of 10,198 shares — an estimated $24K sold.

Alpine Global Management first reported a position in ABUS in Q1 2016 and held it in 3 quarters. The position peaked at $127K in Q4 2020. 122 funds tracked by Wall St. Rank hold ABUS as of Q1 2023.

Alpine Global Management reported no remaining Arbutus Biopharma position as of Q1 2023 after selling out during the quarter.
Alpine Global Management sold 10,198 Arbutus Biopharma shares in Q1 2023, an estimated $24K.
Alpine Global Management first reported a position in Arbutus Biopharma in Q1 2016 and held it in 3 quarters.
Alpine Global Management's Arbutus Biopharma position peaked at $127K in Q4 2020.
122 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.